Kailera Therapeutics

Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive, and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities, Kailera's vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. The company's lead product candidate, ribupatide (KAI-9531), is a once-weekly injectable GLP-1/GIP receptor dual agonist peptide currently being evaluated in a global Phase 3 program.